Zurich, Switzerland, June 07, 2013 --(PR.com
)-- CovalX AG and Bruker Daltonics Inc. (NASDAQ: BRKR) today announced a new agreement that aims to advance protein research in the area of protein interactions and macromolecular characterization by supporting the combination of the two company’s technologies.
This collaboration draws upon CovalX´s experience as a leader in providing novel tools and unique applications for intact protein-protein interaction and macromolecular analysis, and Bruker Daltonics´ cutting-edge life-science systems based on mass spectrometry (MS). By using CovalX’s High-Mass systems, Bruker customers will have access to the analysis of very high molecular weight molecules, with significantly improved detection capabilities in the 150-2000 kDa range. In conjunction with CovalX cross-linking kits for MALDI, the High-Mass system will give Bruker’s customers access to new applications such as intact therapeutic protein aggregates, antibody/antigen interactions and protein complex analysis.
Ryan Wenzel, CSO and Director of North American Operations at CovalX, commented: "This collaboration demonstrates CovalX´s commitment to increasing access to our high mass detection technology for all MALDI platforms, and to work with the manufacturers to find a solution for all customers. We believe the market for protein interaction analysis will continue to grow as it is on the leading edge of analytical development. Furthermore, we expect this growth to be fueled by the distinct advantages presented by the combination of our technologies. By adding the extra benefits provided by CovalX to the industry leading mass spectrometry equipment obtained from Bruker, we hope to support all customers looking to analyze high molecular weight proteins and protein interactions by MALDI."
Currently manufacturing the third generation of high mass detection systems, the HM3, CovalX´s technology is already well recognized as a unique tool for protein-protein interactions analysis, which includes stoichiometry, biotherapeutic aggregation, epitope mapping and immunocomplex characterization; all key applications for the biotech and pharmaceutical industries.
Bruker Daltonics is a leading supplier of life-science systems offering the growing proteomics research community a wide choice of MS-based research tools. Increasing the information content and understanding of protein complexes through the addition of stoichiometric data, inhibition, and aggregation, this molecular interaction data promises to offer new insights for protein researchers worldwide.
“With this strategic collaboration Bruker strengthens its market-leading position in the field of MALDI-TOF Mass Spectrometry by bridging the gap to new application fields in the analysis of protein complexes. The interaction of both CovalX and Bruker technologies will allow the customers to perform protein-protein interaction studies on an advanced level,” said Ralf Schäfer – Global Product Manager MALDI TOF MS of Bruker Daltonics Life Science and Clinical Division (LSC).
This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
CovalX is the market leader in intact protein complex analysis using high mass MALDI based technology with headquarters in Zürich, Switzerland and a North American subsidiary in Saugus, MA. CovalX also supports sales/distribution across Europe, in Japan, Korea and Russia. The technology and applications are protected by a strong patent portfolio. Target groups consist primarily of life science research laboratories and pharmaceutical and biotechnology companies worldwide. CovalX focuses on biotech analytics as the prime area for future growth. The company currently has released its third generation of high mass MALDI detection systems on the market with a range of stabilization chemistries and data analysis software for applications characterizing protein interactions. CovalX also offers a full CRO analytics service featuring all of its novel applications directly to customer.
Based in Zürich, Switzerland, the company is privately held.
Further information on CovalX can be found on the web: www.covalx.com
Address and phone: CovalX AG
Ausstellungstrasse 36, CH-8005 Zürich, Switzerland
Phone: +41 (0)44 585 3961
About Bruker Daltonics
Bruker Daltonics is a leading provider of innovative life science tools based on mass spectrometry. Its substantial investment in research and development allows it to design, manufacture and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, including pharmaceutical companies, biotechnology companies, proteomics companies, molecular diagnostics companies, academic institutions and government agencies. Bruker Daltonics has diverse technology platforms that integrate automated sample preparation and clean-up, advanced front-end AnchorChip™ MALDI targets and API source technology with cutting-edge proprietary MALDI-TOF, MALDI-TOF/TOF, ESI-TOF, ESI-Q-q-TOF, ion trap and FTMS mass analyzers, as well as analysis and bioinformatics software. Bruker Daltonics is also a worldwide leader in supplying mass spectrometry-based systems for substance detection and pathogen identification in security, defense and anti-terrorism applications. Further information is available at:www.bruker.com